Eli Lilly and Company is a few years behind Novo Nordisk A/S in bringing a GLP-1 agonist to market for obesity, but it presented data at the American Diabetes Association (ADA) annual meeting that could give the company a best-in-class portfolio of medicines, including its GLP-1/GIP/glucagon receptor (GGG) triagonist retatrutide, which generated weight loss of up to 24.2% in overweight and obese patients without diabetes at 48 weeks in a Phase II clinical trial presented on 26 June.
Lilly Wows ADA Crowd With Obesity Data Across Three-Drug Incretin Portfolio
Weight Loss Of Up To 24.2% With ‘Triple G’ Retatrutide
Lilly may gain its first US approval in obesity with Mounjaro before the end of 2023, but presented data at ADA for it and two other drugs – retatrutide and orforglipron – that also yielded significant weight loss.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from R&D
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.